Abstract:Abstract Lung cancers represent the second most common cancer and Non-Small Cell Lung Cancer (NSCLC) constitutes 80-85% of all lung cancers. Genes within several cellular pathways have been previously evaluated for their clinical impact in NSCLC. In this investigation, we evaluate genetic mutations found in 50 cancer-critical genes implicated in the signaling pathways RTK/RAS/MAP, TGFβ, PI3K, Wnt, GPCR, p53, JAK/STAT, Notch, and the cell cycle pathway. Some of these mutations have not yet been described or have not been described in NSCLC. The intent of our study is to evaluate these mutations and allow further research into their impact, specifically highlighting mutations that are involved in clinically important pathways. We evaluated mutations found in 59 NSCLC patients at the Prisma Health Cancer Institute. These mutations are part of 2,800 COSMIC (Catalogue of Somatic Mutations in Cancer) hotspot mutations in 50 cancer-critical genes. Each mutation was investigated further using the ClinVar database to identify whether it had been described in NSCLC or other cancers/conditions, its genetic consequence, pathogenesis, possible variations, and origin. A total of 73 unique mutations in 59 NSCLC patients were evaluated. Of the 73 mutations, 17 had not been described at all, 40 had been described in other cancers/conditions, and 16 had been previously described in NSCLC. The known mutations’ effects in other cancers/conditions were categorized as pathogenic, likely pathogenic, likely benign, benign, or uncertain. Novel mutations were found in genes that provide a druggable target, help predict treatment response, are under investigation for their ability to predict treatment response or confer additional clinical utility. Medical management of cancer has benefitted greatly from studies of genetic mutations. Most mutations identified in our patient population had not been described in NSCLC, and a smaller number of those had not been described at all. Further elucidation of these mutations may lead to additional discoveries relevant to NSCLC prognostication and treatment. Citation Format: Miles Rothstein, Phillip Broughton, Ella Markalunas, Avery Funkhouser, Lorie Allen, Julie Martin, W. Jeffery Edenfield, Anna V. Blenda. Evaluation of genetic mutations in non-small cell lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5062.

Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Identification Of Genetic Mutations In Human Lung Cancer By Targeted Sequencing

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Identifying Actionable Variants Using Capture-Based Targeted Sequencing in 563 Patients With Non-Small Cell Lung Carcinoma

Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Abstract 5062: Evaluation of genetic mutations in non-small cell lung cancer patients

Targeted Next-Generation Sequencing of 491 Lung Cancers in Clinical Practice: Implications for Future Detection Strategy and Targeted Therapy

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Comprehensive Profiling and Quantitation of Oncogenic Mutations in Non Small-Cell Lung Carcinoma Using Single Molecule Amplification and Re-Sequencing Technology.

Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy

Mutation and Expression of Multiple Treatment Response-Related Genes in a Population with Locally Advanced Non-Small Cell Lung Cancer.

BRCA mutation in Vietnamese prostate cancer patients: a mixed cross-sectional study and case series

Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing

Association of Pathway Mutations With Survival in Taiwanese Breast Cancers

Association of mutation profiles with metastasis in patients with non-small cell lung cancer

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities

Mutational Landscape Of Early-Stage Non-Small Cell Lung Cancer Patients Using A 451 Gene Panel.

Genomic Profiling of Driver Gene Mutations in Chinese Patients with Non-Small Cell Lung Cancer